We recently reported that monotherapy using the TGase 2 inhibitor GK921 in a xenograft tumor model abrogated RCC growth through p53 stabilization.3 These results suggest the possibility of using TGase 2 inhibitors as a cancer therapy.3 The gene discussed is TP53; the disease is renal cell carcinoma.